Clinical trial · Interventional
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
The Clinical Value of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution in the Immunotherapy of Advanced Primary HCC Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Providing more theoretical basis for the prediction of the efficacy of advanced HCC and helping select better advantaged population of HCC immunotherapy to maximize the benefits of patients By exploring the relationship between the changes of PD-1 expression in peripheral blood T lymphocytes and the clinical efficacy before and after the use of PD-1 / PD-L1 inhibitors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sintilimab | Drug | Sintilimab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy
- description
- Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
- interventionNames
- Drug: Sintilimab
Primary outcomes (1)
- measure
- Compare Progression Free Survival (PFS) Regimen using RECIST 1.1.
- timeFrame
- 24 months
- description
- PFS was defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first. Disease progression was determined based on investigator assessment using response evaluation criteria In solid tumors (RECIST) v1.1.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Willing to participate in the clinical study, fully understand and be informed about the study, and sign the informed consent form; * Age between 18 and 75 years, male or female; * Strictly meet the clinical diagnostic criteria for hepatocellular carcinoma (HCC), confirmed by histology or cytology, with at least one lesion meeting the RECIST 1.1 criteria on CT or MRI examination; * No prior targeted therapy, immunotherapy, or systemic chemotherapy for liver cancer before admission; * Child-Pugh A liver function; Barcelona Clinic Liver Cancer (BCLC) stage B or C; * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; * Normal function of major organs; * Expected survival time of at least 12 weeks or more. Exclusion Criteria: * Patients who have not previously received treatment with Sintilimab or any other PD-L1 or PD-1 antagonist; * Patients with any active autoimmune disease or a history of autoimmune disease, or a history of immunodeficiency; * Patients requiring the use of immunosuppressive drugs; * Known history of allergy to the formulation of Sintilimab or any other component of the antibody formulation; * Patients with other malignant tumors.
References
Publications (0)
Data not yet available